A61K 40/4252
Phosphatases
Official title: {Phosphatases}
A61K40/4252 (Phosphatases) appears on 22 US grants and 60 published applications in this corpus.
Search patents in A61K- Granted patents
- 22
- Published applications
- 60
- Assignees
- 43
- Inventors
- 165
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 5 |
| 2020 | 3 | 5 |
| 2021 | 2 | 7 |
| 2022 | 1 | 6 |
| 2023 | 1 | 7 |
| 2024 | 2 | 4 |
| 2025 | 4 | 6 |
| 2026 | 0 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Protease-activating CD45-gate CAR2 Sep 2025US 12,404,315 B2Allogene Therapeutics, Inc.
- Engineered trimeric CD70 proteins and uses thereof8 Jul 2025US 12,351,618 B2Fred Hutchinson Cancer Center
- Chimeric antigen receptors (CARs), compositions and methods thereof15 Apr 2025US 12,275,787 B2iCell Gene Therapeutics Inc.
- Chimeric antigen receptor cells for treating solid tumor4 Mar 2025US 12,240,915 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Immune cells having co-expressed shRNAS and logic gate systems16 Jul 2024US 12,037,407 B2Arsenal Biosciences, Inc.
- Cell6 Aug 2026US 2026/0224627 A1Autolus Limited
- Alpp-specific variant antigen binding molecules30 Jul 2026US 2026/0216242 A1
- Engineered t cell receptors and engineered immune cells expressing the same23 Jul 2026US 2026/0207748 A1Guangdong Tcrcure Biopharma Technology Co., Ltd.
- Chimeric antigen receptor16 Jul 2026US 2026/0201068 A1Les Hopitaux Universitaires De Geneve
- Protease-activating cd45-gate car9 Jul 2026US 2026/0193310 A1Allogene Therapeutics, Inc.
Most cited
By later US patents
- Methods related to immunostimulatory nucleic acid-induced interferon110US 6,949,520 B1Coley Pharmaceutical GmbH · 2005
- Methods related to immunostimulatory nucleic acid-induced interferon42US 7,776,344 B2Coley Pharmaceutical GmbH · 2010
- Compositions and methods for inhibition of lineage specific antigens21US 10,137,155 B2The Trustees of Columbia University in the City of New York · 2018
- Compositions and methods for inhibition of lineage specific antigens18US 10,912,799 B2The Trustees of Columbia University in the City of New York · 2021
- Methods of inducing a T cell mediated immune response by administering antigen presenting B cells15US 7,195,758 B2Dana-Farber Cancer Institute, Inc. · 2007